1668OCRYODESMO-O1: A French nationwide phase II study on cryoablation in progressing desmoid tumour (DT) patients (pts)
ConclusionsThe study met is primary endpoint with 86% of non-progressive disease at + 12 months, reduced pain and better functional status. CA in the hands of expert interventional radiologists, should be considered in guidelines as a reasonable treatment option for these pts. CA will soon challenge medical therapy as front-line therapy in the forthcoming randomized trial CRYO DESMO-02.Clinical trial identificationNCT02476305.Legal entity responsible for the studyH ôpitaux Universitaires de Strasbourg.FundingFrench National Cancer Institute (INCa).DisclosureJ. Kurtz: Travel / Accommodation / Expenses: PharmaMar; Travel / Accommodation / Expenses: Roche; Advisory / Consultancy, Travel / Accommodation / Expenses: Tesaro; Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca. X. Buy: Honoraria (self): Galil BTG. F. Deschamps: Honoraria (self): BTG; Honoraria (self): Medtronic; Honoraria (self): Covidien. A. gangi: Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Canon medical; Licensing / Royalties: Apriomed; Non-remunerated activity/ies: BTG. All other authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
More News: AstraZeneca | Cancer | Cancer & Oncology | Cervical Cancer | Chemotherapy | Clinical Trials | Disability | France Health | Legislation | Pain | Radiation Therapy | Radiology | Study | Toxicology